This call aims to support research on antimicrobial resistance (AMR) by advancing phage-based therapies for difficult-to-treat bacterial infections. Applicants are expected to design and execute multinational, multicenter randomised controlled trials (RCTs) to provide robust data on the safety and efficacy of phage therapies. Both personalised phage preparations and ready-to-use phage cocktails are eligible for consideration. Innovative methodologies, including computational modeling and artificial intelligence (AI), are encouraged to enhance trial design and implementation.

Key objectives include enabling researchers and healthcare professionals to develop effective phage treatments, providing regulators with actionable data to accelerate approvals, and increasing public awareness about phage therapies. Proposals should address pathogens listed in the WHO Bacterial Priority Pathogens List and integrate patient engagement and ethical, legal, and data compliance considerations.

Applicants must adhere to FAIR data principles, GDPR compliance, and effective intellectual property management. SME participation is strongly encouraged to foster innovation and commercialization. Collaboration between academia, research institutes, industry, and NGOs is critical for achieving the goals of this call.

Opening: 22-05-2025
Deadline(s): 18-09-2025

Data provided by Kooperationsstelle Wissenschaft

This funding opportunity represents a pre-agreed draft that has not yet been officially approved by the European Commission. The final, approved version is expected to be published in the first quarter of 2025. This draft is provided for informational purposes and may be used to preliminarily form consortia and develop project ideas, but it is offered without any guarantees or warranties.